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Intraoperative parathyroid hormone (PTH) monitoring in the setting of the operating room represents a
valuable example of the rationale use of the laboratory diagnostic in a patient-oriented approach. Rapid
intraoperative PTH (ioPTH) assay is a valid tool for an accurate evaluation of the success of parathyroid
surgery. The reliability of the user-friendly portable systems as well as the collaboration between op-
erators and surgical staff allow the one-site monitoring of the ioPTH decrements on the course of the
surgical management of hyperparathyroidism.
The rapid answer provided by an effective decrement of PTH during parathyroidectomy contributes
dramatically to the efﬁcacy of parathyroid surgery and the reduction of the number of re-operations.
Therefore the dose of ioPTH is a valid and reliable support for the success of the intervention of para-
thyroidectomy at controlled costs.
© 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.1. Introduction
Hyperparathyroidism is a disease characterized by the excessive
secretion of PTH, accompanied in the most of patients with hy-
percalcemia, and hypophosphatemia (present only in one third of
cases). The diagnosis of hyperparathyroidism became more
frequent with the introduction of the routine assay of serum cal-
cium; this allowed the identiﬁcation of a greater percentage of
patients with mild or even asymptomatic hyperparathyroidism.
This fact caused a radical change in the clinical scenario, leading to
near the total disappearance clinical ﬁndings frequently observed
in the past such as ﬁbrosocistic osteitis, nephrocalcinosis, and
nephrolithiasis.
Primitive hyperparathyroidism is caused by a parathyroid ade-
noma in the 80% of cases, followed by 15% of hyperplasia, some-
times related to inherited syndromes such as MEN-1 and MEN-2, a
4.5% arising from multiple adenomas, and the 1% by carcinomas.cological and Stomatological
l Vespro 129, 90127, Palermo,
.I. Lo Monte).
ished by Elsevier Ltd. All rights resSecondary hyperparathyroidism originates instead as a compen-
satory response to the chronic hypocalcemic stimulus. These
mechanisms are the basis of a special parathyroid hypertrophy-
hyperplasia characterized by resistance to medical therapy and
need surgery in 25% of cases.
The introduction of intraoperative parathyroid hormone (ioPTH)
assay has profoundly changed the surgical approach in both
primitive and secondary hyperparathyroidism.
This method was introduced for the ﬁrst time in 1988 [1] and
then modiﬁed during the years up to the most recent application of
third-generation immuno-chemiluminescent (ICMA) system with
an incubation time of about 5 min and a rapid dosage of PTHwithin
10min after removal of the hyperfunctioning parathyroid tissue [2].
1.1. Intraoperative assessment of PTH
The intact PTH is a polypeptide produced by parathyroid and
composed of 84 amino acids.
Only parathyroids produce PTH; its half-life is of about 5 min in
plasma. Once a surgical resection of hyperfunctioning tissue is
performed, PTH levels are usually lower in the ﬁrst days due to the
suppressed production in the residual normal glands. The PTH ki-
netics of decrement after parathyroidectomy is characterized by aerved.
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a subsequent curve with a lower elimination speed (21e82 min).
The test is easy to perform and simply to read the results.
At least four different systems, manufactured and marketed by
four separate companies, have been proposed and used for the
determination of ioPTH: QuiCK-Pak Nichols, STATeIOeI-PTH
Future, Immulite Turbo PTH DPC, Elecsys 1010 Roche [3]. All apply
the principle of detection of chemiluminescence signal; the ﬁrst
two are easily transportable in the operating room whereas the
other two are multiparametric analyzers difﬁcult to transport. The
time of response ranges from 7 to 12 min (QuiCK-Pak and
STATeIOeI-PTH) to 15e20 min (Immulite Turbo and Elecsys).
Themodule used for QuiCK-Pak dosing on portable cart contains
a small bench-top micro-centrifuge, an incubator-shaker thermo-
stat, a single reading cell luminometer and an automatic washing
system. The instrument can be utilized directly inside the operating
room or close to it. The total time of the analysis, from blood
sampling to the communication of results to the surgeon, is about
12 min (3 min for the dispensation of the sample, the ball con-
taining the ﬁrst antibody and antibody conjugatewith the substrate
for chemiluminescence, 1 min for sample spinning, a 7-min incu-
bation, 1 min for the washing of the samples and 30 s for reading
the result) [4].
STATeIOeI-PTH kit consists on an instrument on a trolley in the
actual or immediate proximity of the operating room. The assay
utilizes two afﬁnity-puriﬁed goat polyclonal antibodies against
PTH. One anti-PTH antibody (39e84) is coated onto the surface of a
microtiter well; the N-terminal anti-PTH antibody (1e34) is labeled
with isoluminol and lyophilized in the form of an accusphere and
seeded in the wells. During the 5 min incubation time in the STAT-
Shake, intact PTH in the sample is bound and antibody-antigen-
antibody complex is formed. The STAT-Read automatically injects
the activators initiating the chemiluminescence reaction. The light
emission is proportional to the concentration of intact PTH in the
sample. The time needed to perform the assay is 7 min.
The majority of commercial kits dose the PTH fragment 7e84
that has a half-life of a few hours, unlike PTH 1e84which has a half-
life of 2e5 min, producing false negatives. For this reasons our
preferred method is the STATeIOeI-PTH produced by Future Di-
agnostics [5].
Blood samples are taken from a dedicated peripheral vein can-
nula (e.g. vein of the foot) at four different times: at the induction of
anesthesia but before the incision of the neck (baseline sample or
zero time), during the manipulation of suspicious hypersecreting
glands, 10 and 15 min after the last gland excision [6].
The criterion for evaluation of results in primary hyperpara-
thyroidism is based on a cut off of 50% of the decrease of PTH in
plasma levels, while the evaluation of the results in secondary
hyperparathyroidism is based on a cut off of 70% of the decrease of
PTH levels in plasma after 10 min from the resection of the last
gland or of 85% after 15 min. In both cases there is a sensitivity of
85% and a speciﬁcity of 100% when it is applied after 10 min from
surgical resection; sensitivity increases to 97% when sample is
taken after 15 min [7].
For an optimal success of the technique, different organizational
aspects must be considered. Staff must be properly trained for
knowing the function of each part of the system and the possible
drawbacks. It is preferable to have a sufﬁcient notice of at least one
week, whereas parathyroidectomy is almost never an emergency
measure.
The dose of ioPTH during surgery is a good example of the use of
laboratory services oriented towards the patient and is therefore
important a relationship between the laboratory and surgical staff.1.2. The role of ioPTH assay in the surgical timing of
hyperparathyroidism
Preoperative localization of pathological parathyroid glands was
a topic of debate for a long time. Indeed, while for some authors it
was necessary, for others it was quite superﬂuous, and accurate
bilateral neck exploration was the surgical strategy applied.
Until a few years ago the instrumental investigation tools
available had an insufﬁcient diagnostic accuracy, or were charac-
terized by considerable invasiveness with a low cost-beneﬁt ratio.
The disappointing results, especially when compared with those
obtained from surgery performed without preoperative localiza-
tion, showed that these investigations were not helpful.
Technological advances in recent years, however, led to a sig-
niﬁcant improvement in the diagnostic methods, even if they are
burdened by an increase in costs.
Currently sestaMIBI scintigraphy is the imaging method of
choice to localize parathyroids before surgery; the ultrasound scan
is useful in providing more information in the case of cervical
localization, while the CT scan and MRI are more useful in ectopic
localizations [8]. The diagnostic accuracy increases when the ul-
trasound is associated with scintigraphy, with a sensitivity of over
95%; such association, in fact, in case of dubious areas and hyper-
ﬁxation scintigraphy, allows to differentiate between thyroid and
parathyroid tissue origin. It is not possible to differentiate between
adenoma and hyperplasia with US scan. However, a parathyroid
gland increased in volume in more than one typical localization
allows suspecting the presence of a multiglandular involvement
[9].
Although anesthetic progress and the opportunity to practice
parathyroidectomy in regional anesthesia, intra and post-operative
morbidity has to be taken into account in the programming of
assistance.
Signiﬁcant changes in surgical strategy were made possible, in
recent years, thanks to the progress of diagnostic laboratory that
has allowed determining the level of PTH in the operating room
during surgery rapidly.
In hyperparathyroidism, surgical removal of hypersecreting
glands involves a rapid decrease in plasma levels of PTH and its
speed and precocity can immediately show a biological healing. In
this way the intraoperative dosage of PTH can conﬁrm the success
of surgery or change the surgical strategy in time.
For many years the main limitation of ioPTH assay was due to
the times needed to perform radioimmunoassay and immunor-
adiometric methods, sometimes exceeding the 24 h.
The development of portable analyzers and the immuno-
chemiluminescence technique allowed to perform the PTH assay
directly in the setting of the operating room.
The main advantage of the ioPTH assay is represented by the
ability to predict an efﬁcient surgical removal of hyperfunctioning
glands, excluding the possible persistence of residual affected tis-
sues. This provides to the surgeon information not only onwhat has
been excised, but above all on what instead has not been possibly
even removed, suggesting real-time changes in surgical tactics. This
element is of fundamental importance, especially because the most
of the failures in hyperparathyroidism surgery are due to incom-
plete removal, resulting in inadequate or insufﬁcient persistent or
recurrent hyperparathyroidism.
The failures are in fact related to the impossibility to ﬁnd an
adenoma or removal of non-parathyroid tissue (lymph nodes,
thyroid nodules), whose can simulate the appearance of a para-
thyroid pathology [10]. The second cause of failure is the presence
of multiglandular hyperparathyroidism, as in the case of a double
adenoma or hyperplasia that interests the four glands or eventual
ectopic glands. For this reason the surgical technique of choice for
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completeness of parathyroidectomy, was represented by complete
bilateral cervical exploration. The latter implicates the identiﬁca-
tion of at least four parathyroid, to rule out or conﬁrm the presence
of a multiglandular disease, and removal of the glands of patho-
logical appearance (with the possible extemporaneous histological
examination [11].
The rapid ioPTH assay, represents a kind of “extemporaneous
histological biochemical examination”: a signiﬁcant reduction of
PTH levels, in fact, is able to predict healing in almost 100% of the
cases, demonstrating the complete exeresis. On the contrary, the
ﬁnding of elevated PTH values at the end of the intervention is a
sign of persistent disease and suggests to continue the surgical
exploration until the identiﬁcation and removal of all the patho-
logical tissue.
Therefore this method of investigation not only “certiﬁes” the
nature of the parathyroid tissue removed, but also documents the
absence of residual hyperfunctioning tissue, thus making the
exploration of not easily identiﬁed parathyroids not always neces-
sary. The protocol adopted for the ioPTH assay provides four mea-
surement: one baseline at the induction of anesthesia; a second at
the identiﬁcation of pathological glands; a third at 10 min and a
quarter at 15 min after the removal of the glands. A decreased value
of PTH post-ablation greater than 50% (the so-called “cut-off”)
compared to the value pre-ablation (the baseline value) is able to
predict the biological healing with a sensitivity of 98% and a spec-
iﬁcity of 94% and an accuracy of 97%. Failure to decrease PTH in-
dicates the persistence of hyperfunctioning parathyroid tissue [4].
Recently, the international literature reported results and
opinions often widely divergent regarding the accuracy and use-
fulness of this method. There are, in fact, still not ﬁnally resolved
issues regarding the use of ioPTH assay: they are of economic na-
ture (costs and cost-effectiveness), biological (different PTH ki-
netics decay in single adenoma and multiglandular hyperplasia)
and technique. The problems of technical nature are due to the
sensitivity and the speciﬁcity of the type of method used and the
protocol used: there is not an unanimous agreement on the number
and timing of withdrawals, the deﬁnition of withdrawal baseline
and cut-off [12]. As regards the timing of blood samplings pre and
post-excision, the original method implicate that drawings prior to
ablation are made before incision and before removal of the para-
thyroid pathological gland and subsequent after 5 and 10 min from
excision. Other authors suggested different protocols, considering
thewithdrawal baseline the onemade the day before, or at the time
of induction of anesthesia or incision or after mobilization of the
thyroid, but before parathyroid isolation; there were also proposed
blood samplings post-excision performed in very variable times
(from 5 to 90 min). However, it is necessary to deﬁne what is the
baseline, in order to calculate the percentage of decrease post-
excision. In this perspective, it has been proposed to consider as
basal sample the highest value that precedes the ablation (which
very often corresponds to the pre-excision, which increase is
determined precisely by the manipulation of the parathyroid
gland). Other authors argue that consider this value as baseline
withdrawal may cause errors of interpretation. It was therefore
proposed to consider only the value at the time of the incision or
the one that precedes the manipulation of the gland. However it
must be considered that dosages practiced at the time of the inci-
sion can present values higher than 60% compared to those
measured at the induction of anesthesia, making the interpretation
of results more difﬁcult.
Directly related to the issue of the withdrawal is the one
regarding the baseline so-called cut-off, the expected decrease of
PTH after excision, to consider the patient cured. The cut-off of 50%
is a purely empirical limit, which has the advantage of being easy tocalculate. In most cases of hyperparathyroidism caused by a single
parathyroid adenoma and with a very high level preoperative PTH,
the removal of the adenoma results in a rapid drop, signiﬁcantly
higher than the 50%. Instead, when there is a multiglandular
involvement, or when the initials PTH values are lower, the
decrease is slower and more gradual, and therefore a cut-off of 50%
appears to be inadequate, because in many of them, despite a
decrease of more than 50%, it was observed persistence of hyper-
parathyroidism, due to a multiglandular disease not adequately
recognized and treated. For these reasons there were proposed
higher values of cut-off, for example the 70%; these high values,
however, can lead to increase the number of false negatives and
thus unnecessarily prolonged cervical explorations. At present, it is
not possible to identify a cut-off in the dosage of ioPTH able to
predict in 100% of cases, the presence of a multiglandular disease
and this is the major limitation of this method [13].
In secondary hyperparathyroidism a further problem is the
abnormal metabolism of PTH (slowed catabolism, prolonged half-
life) in the case of kidney failure and the need to identify a new
cut-off able to predict the radicalism of the excision and then
healing with an acceptable accuracy, as that of 50%, already iden-
tiﬁed for primitive hyperparathyroidism is totally inadequate. A
cut-off of 70% at 10 min may be sufﬁcient to predict the healing
(deﬁned as the absence of persistent hyperparathyroidism) with a
sensitivity 85% and speciﬁcity of 100%. In some cases, however, may
be needed more blood samplings at different longer times and a
cut-off even above 75% [14].
Tertiary hyperparathyroidism shows the same problems as
multiglandular primary forms, and then a cut-off of 50% at 10 min
would be sufﬁcient to predict the healing with a sensitivity 84% and
speciﬁcity of 100%, even if sometimes further withdrawals are
needed with a cut-off of 70% [15]. The rapid ioPTH assay can be also
very helpful in relapses [16].
2. Conclusions
Despite the evolution and the different drugs available, para-
thyroidectomy is an essential therapeutic element in the treatment
of hyperparathyroidism, particularly in patients with secondary
hyperparathyroidism in hemodialysis with elevated PTH levels
(>400 pg/ml) and signs of myeloﬁbrosis associatedwith at least one
of the following factors resistant to medical therapy (calcimi-
metics): hypercalcemia, hyperphosphatemia, ectopic progressive
calciﬁcations, severe clinical symptoms and calciphylaxis without
excluding patients undergoing kidney transplantation [17e20]. In
agreement with the international literature, the use of ioPTH assay
can be considered the “gold standard” in the context of the timing
of surgical hyperparathyroidism. The easily use of the portable
system and reliability of analytical results, combined with a
sequential approach guided by the surgeon make the intra-
operative monitoring of parathyroid hormone directly into the
operating room an important tool for the surgeon and induces
improvements in the hospital course and in the treatment of the
patient. As for the programming of the commitment of the staff, it is
needed enough time to notice, taking into account that the in-
terventions of parathyroidectomy are not considered emergency
operations. Therefore it is advisable to performmultiple operations
on the same day, as the cost of the assay would be amortized by
producing the calibration curves only once a day.
Furthermore, the possibility to use this method in the in-
terventions of parathyroidectomy, contributes to a considerable
saving linked above all to the reduction of the number of reoper-
ations. Therefore the dose of ioPTH is a valid and reliable support
for the success of the intervention of parathyroidectomy at
controlled costs.
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